Technology
Health
Pharmaceutical

Allena Pharmaceuticals

$4.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-2.59%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALNA and other stocks, options, ETFs, and crypto commission-free!

About

Allena Pharmaceuticals, Inc. Common Stock, also called Allena Pharmaceuticals, is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Read More Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

Employees
Headquarters
Newton, Massachusetts
Founded
2011
Market Cap
93.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
58.11K
High Today
$4.92
Low Today
$4.41
Open Price
$4.73
Volume
96.35K
52 Week High
$15.65
52 Week Low
$4.41

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2017 IPO
US

News

NasdaqMay 8

All You Need to Know About Allena Pharmaceuticals, Inc. (ALNA) Rating Upgrade to Buy

Investors might want to bet on Allena Pharmaceuticals, Inc. (ALNA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. ...

51

Earnings

-$0.58
-$0.51
-$0.45
-$0.38
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.